(Q38712213)

English

Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology

scientific article published on March 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

2

object named as

L Puig

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

José Luis López Estebaranz

0 references

author name string

E Daudén

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

C Ferrándiz

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

J L Sánchez-Carazo

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

J M Hernanz-Hermosa

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

1 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

30 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1-18

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

The Delphi method: an efficient procedure to generate knowledge

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Treatment of scalp psoriasis: review of the evidence and Delphi consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Definition of treatment goals for moderate to severe psoriasis: a European consensus

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Psodisk, a new visual method for assessing the burden of psoriasis on patients

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Consensus guidelines for the management of plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Critical review of generic and dermatology-specific health-related quality of life instruments

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Current severe psoriasis and the rule of tens.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

National Psoriasis Foundation clinical consensus on disease severity

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Maximizing patient adherence for optimal outcomes in psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Combining traditional systemic and biologic therapies for psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The diagnosis and treatment of early psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The concept of psoriasis as a systemic inflammation: implications for disease management

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Identifiers

10.1111/JDV.13542

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38712213&oldid=1779559848"